ASXC - Asensus Surgical, Inc. Stock Price, Fair Value and News

0.24USD-0.01 (-4.00%)Market Closed

Market Summary

USD0.24-0.01

Market Closed

-4.00%

ASXC Stock Price

View Fullscreen

ASXC RSI Chart

ASXC Valuation

Market Cap

66.2M

Price/Earnings (Trailing)

-0.84

Price/Sales (Trailing)

7.72

EV/EBITDA

-0.66

Price/Free Cashflow

-1.03

ASXC Price/Sales (Trailing)

ASXC Profitability

Operating Margin

7.33%

EBT Margin

-910.80%

Return on Equity

-234.73%

Return on Assets

-132.74%

Free Cashflow Yield

-96.92%

ASXC Fundamentals

ASXC Revenue

Revenue (TTM)

8.6M

Rev. Growth (Yr)

120.41%

Rev. Growth (Qtr)

398.71%

ASXC Earnings

Earnings (TTM)

-78.4M

Earnings Growth (Yr)

3.66%

Earnings Growth (Qtr)

5.91%

Breaking Down ASXC Revenue

Last 7 days

-3.8%

Last 30 days

4.2%

Last 90 days

-13.8%

Trailing 12 Months

-63.2%

How does ASXC drawdown profile look like?

ASXC Financial Health

Current Ratio

2.88

ASXC Investor Care

Shares Dilution (1Y)

11.83%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.0M	7.1M	5.6M	8.6M
2022	7.2M	7.1M	7.1M	7.1M
2021	4.7M	5.1M	6.9M	8.2M
2020	7.0M	4.0M	2.8M	3.2M
2019	21.5M	18.8M	15.4M	8.5M
2018	9.9M	14.7M	20.0M	24.1M
2017	3.6M	5.0M	3.8M	7.1M
2016	0	0	1.8M	1.7M
2014	1.2M	787.0K	486.0K	401.0K
2013	2.0M	1.8M	1.6M	1.4M
2012	0	0	0	2.1M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Asensus Surgical, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 21, 2024	shameze rampertab	sold (taxes)	-10,909	0.25	-43,638	evp, chief financial officer
Apr 21, 2024	shameze rampertab	acquired	-	-	81,521	evp, chief financial officer
Apr 21, 2024	fernando anthony c. j.	sold (taxes)	-29,857	0.25	-119,429	president and ceo
Apr 21, 2024	fernando anthony c. j.	acquired	-	-	271,739	president and ceo
Feb 04, 2024	fernando anthony c. j.	acquired	-	-	1,042,770	president and ceo
Feb 04, 2024	shameze rampertab	sold (taxes)	-40,599	0.27	-150,367	evp, chief financial officer
Feb 04, 2024	fernando anthony c. j.	sold (taxes)	-130,834	0.27	-484,572	president and ceo
Feb 04, 2024	shameze rampertab	acquired	-	-	280,909	evp, chief financial officer
Dec 14, 2023	starling william n jr	bought	5,077	0.28	18,134	-
Dec 14, 2023	starling william n jr	sold	-5,077	0.28	-18,134	-

Which funds bought or sold ASXC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-6.00	18.00	-%
Apr 23, 2024	Alpha Cubed Investments, LLC	unchanged	-	-1,334	3,450	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-0.78	-1,282	3,228	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-228	-	-%
Apr 18, 2024	MGO Private Wealth, LLC	new	-	2,300	2,300	-%
Apr 18, 2024	Mirador Capital Partners LP	unchanged	-	-9,779	25,300	-%
Apr 16, 2024	Asset Dedication, LLC	unchanged	-	-	-	-%
Apr 15, 2024	Future Financial Wealth Managment LLC	new	-	178	178	-%
Apr 12, 2024	Gleason Group, Inc.	unchanged	-	-1.00	5.00	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	added	72.56	4,346	8,532	-%

Are Funds Buying or Selling ASXC?

Are funds buying ASXC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ASXC

No. of Funds

Unveiling Asensus Surgical, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 20, 2023	state street corp	0.35%	817,129	SC 13G/A
Jul 08, 2022	blackrock inc.	1.6%	3,684,318	SC 13G
Feb 10, 2022	state street corp	5.42%	12,703,273	SC 13G
Feb 04, 2022	blackrock inc.	6.7%	15,793,991	SC 13G

Recent SEC filings of Asensus Surgical, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 03, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Feb 06, 2024	4	Insider Trading
Feb 06, 2024	4	Insider Trading

Peers (Alternatives to Asensus Surgical, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.02%	16.40%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	1.30%	-3.37%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	12.50%	-31.24%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	5.60%	-56.15%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.33	1.07	5.77%	8.23%

Asensus Surgical, Inc. News

Latest updates

Asensus Surgical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	398.7%	5,431,000	1,089,000	1,081,000	976,000	2,464,000	2,563,000	994,000	1,066,000	2,476,000	2,571,000	1,102,000	2,083,000	1,106,500	814,000	655,000	600,000	687,000	2,024,000	3,639,000	2,181,000	7,524,000
Gross Profit	165.5%	1,166,000	-1,780,000	-1,993,000	-1,971,000	166,000	-1,841,000	-1,353,000	-757,000	189,000	-779,000	-1,245,000	-1,029,000	514,000	-609,000	-758,000	-1,138,000	-10,195,000	-1,422,000	-297,000	-286,000	1,889,000
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,014,000	2,110,000	96,427,000	22,197,000	21,640,000	20,114,000
Operating Expenses	-7.1%	17,164,000	18,479,000	18,870,000	20,377,000	18,293,000	17,191,000	18,214,000	18,196,000	15,873,000	16,659,000	14,839,000	14,384,000	14,222,500	14,553,000	13,608,000	16,014,000	10,245,500	96,427,000	22,197,000	-	-
S&GA Expenses	-8.6%	3,781,000	4,138,000	4,449,000	4,553,000	3,820,000	3,615,000	3,602,000	3,719,000	3,229,000	3,551,000	3,562,000	3,053,000	2,773,500	3,136,000	2,901,000	4,253,000	5,589,000	6,883,000	7,868,000	7,674,000	7,901,000
R&D Expenses	-7.3%	8,614,000	9,290,000	8,980,000	10,139,000	8,520,000	6,741,000	7,253,000	6,428,000	6,575,000	4,469,000	4,089,000	4,215,000	3,755,500	4,673,000	4,257,000	3,934,000	4,634,000	5,884,000	6,295,000	5,655,000	6,439,000
EBITDA Margin	35.2%	-8.73	-13.47	-10.74	-10.69	-10.08	-9.78	-9.37	-8.37	-7.17	-8.32	-11.01	-12.40	-18.24	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-30,000	99,000	141,000	200,000	293,000	65,000	5,000	7,000	19,000	-	-	-	200,000	1,230,000	1,061,000	1,116,000	810,500
Income Taxes	213.2%	178,500	57,000	-12,000	90,000	94,000	55,000	85,000	84,000	229,000	32,000	2,000	-38,000	-130,000	2,000	-691,000	-697,000	-575,000	-1,070,000	-869,000	-610,000	-823,000
Earnings Before Taxes	6.6%	-17,057,000	-18,261,000	-20,674,000	-22,127,000	-17,796,000	-18,869,000	-19,534,000	-19,044,000	-15,652,000	-16,037,000	-13,170,000	-17,378,000	-13,921,500	-15,080,000	-14,531,000	-17,295,000	-14,308,000	-98,841,000	-21,040,000	-23,135,000	-7,264,000
EBT Margin	35.2%	-9.11	-14.06	-11.22	-11.19	-10.62	-10.30	-9.89	-8.86	-7.56	-8.82	-11.66	-13.08	-19.16	-	-	-	-	-	-	-	-
Net Income	5.9%	-17,235,000	-18,318,000	-20,662,000	-22,218,000	-17,890,000	-18,924,000	-19,619,000	-19,128,000	-15,881,000	-16,069,000	-13,172,000	-17,340,000	-13,791,500	-15,082,000	-13,840,000	-16,598,000	-13,733,000	-97,771,000	-20,171,000	-22,525,000	-6,441,000
Net Income Margin	35.1%	-9.14	-14.10	-11.25	-11.24	-10.66	-10.36	-9.95	-8.91	-7.59	-8.80	-11.63	-12.89	-18.68	-	-	-	-	-	-	-	-
Free Cashflow	12.5%	-13,447,000	-15,371,000	-18,058,000	-17,312,000	-14,428,000	-15,115,000	-14,484,000	-16,189,000	-13,702,000	-9,140,000	-8,553,000	-10,632,000	-12,765,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-16.5%	59.00	71.00	78.00	97.00	116	129	147	167	186	200	212	224	78.00	80.00	76.00	84.00	75.00	98.00	203	217	239
Current Assets	-20.8%	36.00	46.00	55.00	72.00	87.00	104	109	119	113	135	174	182	34.00	38.00	34.00	40.00	28.00	47.00	69.00	82.00	102
Cash Equivalents	-21.1%	17.00	22.00	8.00	19.00	6.00	15.00	12.00	26.00	19.00	61.00	158	166	18.00	21.00	16.00	23.00	11.00	23.00	24.00	26.00	22.00
Inventory	7.3%	7.00	7.00	9.00	9.00	8.00	9.00	8.00	9.00	9.00	12.00	13.00	11.00	10.00	11.00	11.00	10.00	11.00	14.00	20.00	15.00	11.00
Net PPE	-3.0%	9.00	9.00	9.00	9.00	10.00	9.00	9.00	10.00	11.00	10.00	10.00	9.00	10.00	9.00	7.00	6.00	5.00	5.00	6.00	6.00	6.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80.00	80.00	80.00
Liabilities	9.4%	26.00	23.00	17.00	17.00	16.00	16.00	16.00	16.00	17.00	18.00	16.00	18.00	17.00	18.00	16.00	17.00	19.00	34.00	72.00	70.00	71.00
Current Liabilities	4.2%	13.00	12.00	11.00	11.00	10.00	10.00	10.00	9.00	10.00	9.00	8.00	10.00	10.00	12.00	10.00	13.00	13.00	12.00	23.00	20.00	22.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	3.00	3.00	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	2.00	1.00	0.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	3.00	-	-	-	-	-	-	-
Shareholder's Equity	-29.3%	33.00	47.00	62.00	80.00	100	113	131	151	169	182	196	206	62.00	62.00	60.00	67.00	56.00	64.00	131	147	169
Retained Earnings	-1.9%	-939	-922	-903	-883	-860	-843	-824	-804	-785	-769	-753	-740	-722	-709	-694	-680	-663	-649	-552	-531	-509
Additional Paid-In Capital	0.2%	973	971	966	964	963	961	959	957	955	950	947	945	781	770	755	750	720	716	683	679	677
Shares Outstanding	0.3%	265	264	240	239	237	236	237	236	235	224	234	205	-	-	-	-	-	-	-	-	-
Float	-	-	-	120	-	-	-	93.00	-	-	-	732	-	-	-	29.00	-	-	-	245	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	11.1%	-13,374	-15,049	-17,956	-17,248	-14,053	-14,654	-14,287	-15,943	-13,172	-9,002	-8,248	-10,237	-12,765	-8,774	-12,659	-12,477	-14,368	-19,578	-15,343	-24,195	-12,852
Share Based Compensation	-0.7%	2,005	2,019	1,978	1,916	2,055	2,033	2,083	2,245	2,840	2,961	1,842	1,786	2,111	1,944	1,933	1,923	1,781	3,391	3,355	2,981	2,345
Cashflow From Investing	-64.3%	7,427	20,778	6,564	29,737	6,327	18,037	128	23,045	-30,598	-88,370	-305	-395	-	-	-1.00	-2.00	15,920	9,797	12,940	28,988	-17,900
Cashflow From Financing	-98.2%	172	9,743	194	-483	-	-1.00	5.00	-336	1,564	33.00	503	159,605	8,936	13,649	6,081	24,704	-14,344	8,730	268	-263	10,311

ASXC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue	$ 8,577	$ 7,087
Cost of revenue:
Cost of revenue	13,155	10,872
Gross loss	(4,578)	(3,785)
Operating Expenses:
Research and development	37,023	28,942
Sales and marketing	16,921	14,756
General and administrative	19,155	20,172
Amortization of intangible assets	453	7,708
Change in fair value of contingent consideration	964	(1,115)
Impairment of property and equipment	374	1,431
Total operating expenses	74,890	71,894
Operating loss	(79,468)	(75,679)
Other Income (Expense), net
Change in fair value of warrant liabilities	1,232	0
Interest income	1,553	1,141
Interest expense	0	(410)
Other expense, net	(1,436)	(295)
Total other income (expense), net	1,349	436
Loss before income taxes	(78,119)	(75,243)
Income tax expense	(314)	(318)
Net loss	$ (78,433)	$ (75,561)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)	$ (0.31)	$ (0.32)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)	249,685	236,492
Comprehensive loss:
Net loss	$ (78,433)	$ (75,561)
Foreign currency translation gain (loss)	1,280	(1,867)
Unrealized gain (loss) on available-for-sale investments	496	(257)
Comprehensive loss	(76,657)	(77,685)
Product [Member]
Revenue:
Revenue	5,519	4,327
Cost of revenue:
Cost of revenue	6,866	5,303
Service [Member]
Revenue:
Revenue	1,052	1,373
Cost of revenue:
Cost of revenue	2,293	2,174
Lease [Member]
Revenue:
Revenue	2,006	1,387
Cost of revenue:
Cost of revenue	$ 3,996	$ 3,395

ASXC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 17,096	$ 6,329
Short-term investments, available-for-sale	3,971	64,195
Accounts receivable, net	3,508	2,256
Inventories	7,172	8,284
Prepaid expenses	3,143	3,584
Employee retention tax credit receivable	0	554
Other current assets	1,496	1,671
Total Current Assets	36,386	86,873
Restricted cash	1,642	1,141
Long-term investments, available-for-sale	0	3,865
Inventories, net of current portion	4,043	5,469
Property and equipment, net	8,959	9,542
Intellectual property, net	1,237	1,576
Net deferred tax assets	44	174
Operating lease right-of-use assets, net	5,165	4,950
Other long-term assets	1,610	2,463
Total Assets	59,086	116,053
Current Liabilities:
Accounts payable	4,145	3,348
Accrued employee compensation and benefits	5,390	4,508
Accrued expenses and other current liabilities	1,636	1,293
Operating lease liabilities - current portion	1,036	800
Deferred revenue	421	465
Total Current Liabilities	12,628	10,414
Long-Term Liabilities:
Deferred revenue - less current portion	290	0
Contingent consideration	2,220	1,256
Warrant liabilities	5,888	0
Noncurrent operating lease liabilities	4,646	4,738
Total Liabilities	25,672	16,408
Stockholders' Equity:
Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2023 and December 31, 2022; 264,921,526 and 236,895,440 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	265	237
Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Additional paid-in capital	973,129	962,731
Accumulated deficit	(939,368)	(860,935)
Accumulated other comprehensive loss	(612)	(2,388)
Total Stockholders' Equity	33,414	99,645
Total Liabilities and Stockholders' Equity	59,086	116,053
Intellectual Property [Member]
Current Assets:
Intellectual property, net	$ 1,237	$ 1,576

About Asensus Surgical, Inc.

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

CEO	Mr. Anthony Fernando
WEBSITE	asensus.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	183

Asensus Surgical, Inc. Frequently Asked Questions

What is the ticker symbol for Asensus Surgical, Inc.? What does ASXC stand for in stocks?

ASXC is the stock ticker symbol of Asensus Surgical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Asensus Surgical, Inc. (ASXC)?

As of Tue Apr 23 2024, market cap of Asensus Surgical, Inc. is 66.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASXC stock?

You can check ASXC's fair value in chart for subscribers.

What is the fair value of ASXC stock?

You can check ASXC's fair value in chart for subscribers. The fair value of Asensus Surgical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Asensus Surgical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASXC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Asensus Surgical, Inc. a good stock to buy?

The fair value guage provides a quick view whether ASXC is over valued or under valued. Whether Asensus Surgical, Inc. is cheap or expensive depends on the assumptions which impact Asensus Surgical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASXC.

What is Asensus Surgical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ASXC's PE ratio (Price to Earnings) is -0.84 and Price to Sales (PS) ratio is 7.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASXC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Asensus Surgical, Inc.'s stock?

In the past 10 years, Asensus Surgical, Inc. has provided -0.418 (multiply by 100 for percentage) rate of return.